May 6, 2016
Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma
New programs respond to unmet needs described by the GBM community May 06, 2016 07:35 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today it will deliver new programs to support the glioblastoma (GBM) community during Brain Tumor Awareness Month. Last year,… Read More
learn more
May 5, 2016
Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer
Website and traveling exhibit to support glioblastoma community May 05, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today the availability of a new online resource to raise awareness of glioblastoma (GBM) and share stories of inspiration with the GBM… Read More
learn more
May 4, 2016
Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune
More than 112 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma May 04, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Blue Cross Blue Shield of Michigan now covers Optune… Read More
learn more
April 26, 2016
Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.
Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients April 26, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Physicians at more than 360 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune to newly diagnosed… Read More
learn more
April 25, 2016
FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy April 25, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today that the RTOG Foundation will conduct a phase 2 pilot trial testing… Read More
learn more
April 15, 2016
OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024 – Research and Markets
April 15, 2016 08:46 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024” report to their offering. Glioblastoma multiforme (GBM) is characterized as a… Read More
learn more
April 7, 2016
Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016
New Findings Show TTFields May Be Optimized to Prevent Migration and Invasion of Glioma Cells April 07, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) will present three preclinical abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2016… Read More
learn more
April 5, 2016
Novocure to Report First Quarter 2016 Financial Results
April 05, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a conference call and webcast to discuss its first quarter 2016 financial results at 5 p.m. EDT on Monday, May 9, 2016. Schedule for press release… Read More
learn more
March 31, 2016
Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields
Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in Culture March 31, 2016 11:02 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today that Novocure’s inovitro™ laboratory research… Read More
learn more
March 9, 2016
Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma
March 09, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that a computational study analyzing the effect of transducer layout on Tumor Treating Fields, or TTFields, distribution has been published in the International Journal of Radiation Oncology • Biology • Physics, also… Read More
learn more
